TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TCON opened at $0.03 on Thursday. The stock’s 50 day moving average price is $0.08 and its 200 day moving average price is $0.54. The stock has a market cap of $107,585.50, a P/E ratio of 0.01 and a beta of 1.43. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.